- Home
- RNA vs TGTX Comparison
RNA vs TGTX Comparison
Compare RNA & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RNA
- TGTX
- Stock Information
- Founded
- RNA 2012
- TGTX 1993
- Country
- RNA United States
- TGTX United States
- Employees
- RNA N/A
- TGTX N/A
- Industry
- RNA Biotechnology: Pharmaceutical Preparations
- TGTX Biotechnology: Pharmaceutical Preparations
- Sector
- RNA Health Care
- TGTX Health Care
- Exchange
- RNA Nasdaq
- TGTX Nasdaq
- Market Cap
- RNA 4.0B
- TGTX 4.2B
- IPO Year
- RNA 2020
- TGTX 1995
- Fundamental
- Price
- RNA $46.92
- TGTX $28.07
- Analyst Decision
- RNA Strong Buy
- TGTX Strong Buy
- Analyst Count
- RNA 15
- TGTX 5
- Target Price
- RNA $68.40
- TGTX $40.80
- AVG Volume (30 Days)
- RNA 3.7M
- TGTX 2.8M
- Earning Date
- RNA 08-07-2025
- TGTX 08-04-2025
- Dividend Yield
- RNA N/A
- TGTX N/A
- EPS Growth
- RNA N/A
- TGTX N/A
- EPS
- RNA N/A
- TGTX 0.36
- Revenue
- RNA $10,729,000.00
- TGTX $454,069,000.00
- Revenue This Year
- RNA N/A
- TGTX $84.00
- Revenue Next Year
- RNA $196.18
- TGTX $39.26
- P/E Ratio
- RNA N/A
- TGTX $77.25
- Revenue Growth
- RNA 1.23
- TGTX 30.96
- 52 Week Low
- RNA $21.51
- TGTX $20.39
- 52 Week High
- RNA $56.00
- TGTX $46.48
- Technical
- Relative Strength Index (RSI)
- RNA 71.22
- TGTX 32.04
- Support Level
- RNA $45.06
- TGTX $25.28
- Resistance Level
- RNA $47.24
- TGTX $28.01
- Average True Range (ATR)
- RNA 2.58
- TGTX 1.47
- MACD
- RNA 0.50
- TGTX -0.37
- Stochastic Oscillator
- RNA 81.95
- TGTX 24.29
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.
About TGTX TG Therapeutics Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.